Managed AI Services for Pharmaceuticals

In pharma, a deployed AI system lives under GxP, which means operation itself must be validated, controlled, and documented, not just the original build. Models supporting pharmacovigilance, regulatory submissions, and evidence synthesis cannot drift unnoticed when the FDA can audit your computerized systems at any time. Managed AI Services operates your validated AI under change control that preserves GxP state: every monitored metric, every incident, and every model update is documented to the standard your QA and regulatory affairs teams require. We keep adverse-event detection sensitive, keep submission tooling accurate against current guidance, and keep the validation evidence current, so your systems stay audit-ready in production.

Book a consultation All Pharmaceuticals AI

How we deliver it

Managed AI Services, built for pharmaceuticals

We operate validated systems under GxP-compliant change control, so any update is risk-assessed, tested, approved, and documented before it reaches a controlled environment.

We run continuous evaluation tied to your validation protocols, with monitoring evidence captured in audit-ready form for FDA and inspection readiness.

We own incident response under SLA with deviation handling that fits your quality system, including documented root cause and CAPA linkage.

We maintain the system against evolving FDA and ICH guidance, so pharmacovigilance and submission tooling stay current without falling out of validated state.

Where it pays off in pharmaceuticals

Pharmacovigilance monitoring

We keep adverse-event detection and case-processing models sensitive and calibrated, monitoring for missed signals against your safety thresholds.

Validated system upkeep

We operate AI in validated state with change control, so updates preserve GxP compliance and keep validation evidence current for inspection.

Submission tooling accuracy

We maintain document generation and review tools against current regulatory guidance, with quality tracked so submission content stays reliable.

Evidence synthesis quality

We monitor literature and evidence-synthesis systems for accuracy and citation integrity, keeping outputs defensible for medical and regulatory use.

Pharma clients keep validated AI systems in audit-ready state continuously, so pharmacovigilance signal detection holds its sensitivity and inspections find documented evidence rather than gaps.

Pharmaceuticals AI, answered

Every change runs through GxP-compliant change control: risk assessment, testing against validation protocols, approval, and documentation before it touches a controlled environment. We treat the operated system as a validated computerized system throughout, so it stays inspection-ready rather than drifting out of qualification.

Yes. We maintain audit-ready monitoring evidence, change records, deviation handling, and CAPA linkage in line with your quality system. When an inspector asks how the system has performed and been controlled, the documentation already exists and is traceable.

Guidance changes are managed on our roadmap. We assess the impact on pharmacovigilance and submission tooling, update under change control, and revalidate the affected functions, so the system stays both current and compliant rather than one or the other.